TNFRSF17 and plasma cell myeloma: Drugs like proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (ImiDs; thalidomide, lenalidomide, pomalidomide), and B-cell maturation antigen (BCMA)-targeted therapies are also used to target specific proteins on myeloma cells [13,14,15].